Deep Vein Thrombosis (DVT)

Deep vein thrombosis (DVT) is caused by the formation of venous blood clots in the arms and legs. This page includes information on technologies to treat DVT  using catheter based interventions and thrombolysis. 

FDA Clears Pradaxa as First Oral Anticoagulant for Children. Dabigatran, has been cleared by the FDA
News | Antiplatelet and Anticoagulation Therapies | June 21, 2021
June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate (...
Videos | Coronavirus (COVID-19) | April 01, 2021
Behnood Bikdeli M.D., a cardiologist at the Brigham and Women’s Hospital, Harvard Medical School, Boston, offers an...
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Additional figure included in the JACC article.

Feature | Antiplatelet and Anticoagulation Therapies | March 22, 2021 | By Dave Fornell, Editor
A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal...
The FDA has granted 510(k) clearance for the Inari Medical Inc. FlowTriever system for the treatment of clot in transit (CIT) in the right atrium. FlowTriever is the first thrombectomy system not requiring a cardiopulmonary bypass circuit to be FDA cleared for blood clots in the right atrium. 

The FDA has granted 510(k) clearance for the Inari Medical Inc. FlowTriever system for the treatment of clot in transit (CIT) in the right atrium. FlowTriever is the first thrombectomy system not requiring a cardiopulmonary bypass circuit to be FDA cleared for blood clots in the right atrium. 

News | Thrombectomy Devices | January 08, 2021
January 8, 2021 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Inari Medical Inc....
Thrombus formation in the aortic arch in a 46-year-old COVID patients in the ICU. Three trials are underway to find which anticoagulant strategy is best to treat moderate and critically ill patients where COVID-causes venous thrombo-embolism (VTE) is a major cause of complications. Image courtesy of Margarita Revzin et al.

Thrombus formation in the aortic arch in a 46-year-old COVID patients in the ICU. Three trials are underway to find which anticoagulant strategy is best to treat moderate and critically ill patients where COVID-causes venous thrombo-embolism (VTE) is a major cause of complications. Image courtesy of Margarita Revzin et al. 

Feature | Coronavirus (COVID-19) | December 23, 2020
December 23, 2020 — Three clinical trial platforms working together to test the effects of full doses of anticoagulants...
Abre venous self-expanding stent found safe, effective in treating challenging deep venous lesions was approved by the FDA.
News | Venous Therapies | October 26, 2020
October 26, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic Abre venous self-expanding...
The NIH is heading three studies looking at various blood thinners and anticoagulants to treat COVID-19 patients with VTE.
News | Coronavirus (COVID-19) | September 11, 2020
September 11, 2020 — The National Institutes of Health (NIH) has launched two of three adaptive clinical trials...
Bilateral pulmonary embolisms seen on spectral CT. Photo courtesy of Siemens Healthineers.

Bilateral pulmonary embolisms seen on spectral CT. Photo courtesy of Siemens Healthineers.

Feature | Coronavirus (COVID-19) | May 04, 2020
May 4, 2020 — A committee comprised of vascular surgeons, medical physicians and technologists from the University of...
The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies | December 27, 2019
December 27, 2019 — The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of...
The ClotTriever system (Inari Medical), a mechanical thrombectomy system FDA 510(k) cleared for the nonsurgical removal of soft thrombi and emboli from peripheral blood vessels.  #VIVA19 #VIVA2019

The ClotTriever system (Inari Medical), a mechanical thrombectomy system FDA 510(k) cleared for the nonsurgical removal of soft thrombi and emboli from peripheral blood vessels. 

 

News | Deep Vein Thrombosis (DVT) | November 14, 2019
November 7, 2019 — The ClotTriever Outcomes (CLOUT) Registry is evaluating real-world patient outcomes following...
Fragmin (dalteparin sodium) injection was cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Fragmin (dalteparin sodium) injection is now cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Technology | Antiplatelet and Anticoagulation Therapies | May 17, 2019
May 17, 2019 — The U.S. Food and Drug Administration (FDA) this week approved Fragmin (dalteparin sodium) injection,...
Illustration showing the self-expanding deployment of the Boston Scientific Vici venous stent in the iliofemoral vein.

Illustration showing the self-expanding deployment of the Vici stent in the iliofemoral vein. 

Technology | Venous Therapies | May 06, 2019
May 6, 2019 — The U.S Food and Drug Administration (FDA) has cleared the Boston Scientific Vici Venous Stent System for...
JETi Thrombectomy System Safe and Effective for Deep Vein Thrombosis
News | Thrombectomy Devices | February 12, 2019
February 12, 2019 — A study presented at the 2018 annual meeting of the Cardiovascular and Interventional Radiology...
An assortment of Boston Scientific AngioJet rheolytic thrombectomy catheters. These devices use high-velocity saline jets to entrain thrombus, resulting in microfragmentation and removal. Thrombectomy is also referred to as embolectomy.

An assortment of Boston Scientific AngioJet rheolytic thrombectomy catheters. These devices use high-velocity saline jets to entrain thrombus, resulting in microfragmentation and removal.

Feature | Thrombectomy Devices | January 22, 2019 | Dave Fornell, Editor
Catheter-based blood clot removal a decade ago was a standard of care for acute coronary revascularization, but...
First Commercial Ekos Control Unit 4.0 Products Shipped to Europe
News | Thrombectomy Devices | November 21, 2018
November 21, 2018 — BTG plc announced the first Ekos CU 4.0 units have been shipped from BTG’s facility in Bothell,...